BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28650658)

  • 1. Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
    Mao R; Shao J; Zhu K; Zhang Y; Ding H; Zhang C; Shi Z; Jiang H; Sun D; Duan W; Luo C
    J Med Chem; 2017 Jul; 60(14):6289-6304. PubMed ID: 28650658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
    Chan-Penebre E; Kuplast KG; Majer CR; Boriack-Sjodin PA; Wigle TJ; Johnston LD; Rioux N; Munchhof MJ; Jin L; Jacques SL; West KA; Lingaraj T; Stickland K; Ribich SA; Raimondi A; Scott MP; Waters NJ; Pollock RM; Smith JJ; Barbash O; Pappalardi M; Ho TF; Nurse K; Oza KP; Gallagher KT; Kruger R; Moyer MP; Copeland RA; Chesworth R; Duncan KW
    Nat Chem Biol; 2015 Jun; 11(6):432-7. PubMed ID: 25915199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of 5-benzylidene-2-phenylthiazolones as potent PRMT5 inhibitors by virtual screening, structural optimization and biological evaluations.
    Zhu K; Tao H; Song JL; Jin L; Zhang Y; Liu J; Chen Z; Jiang CS; Luo C; Zhang H
    Bioorg Chem; 2018 Dec; 81():289-298. PubMed ID: 30172110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
    Zhu K; Song JL; Tao HR; Cheng ZQ; Jiang CS; Zhang H
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3693-3699. PubMed ID: 30366617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations.
    Zhu K; Jiang C; Tao H; Liu J; Zhang H; Luo C
    Bioorg Med Chem Lett; 2018 May; 28(9):1476-1483. PubMed ID: 29628326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Novel PRMT5 Inhibitors by Virtual Screening and Biological Evaluations.
    Tao H; Yan X; Zhu K; Zhang H
    Chem Pharm Bull (Tokyo); 2019; 67(4):382-388. PubMed ID: 30930442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening.
    Ye Y; Zhang B; Mao R; Zhang C; Wang Y; Xing J; Liu YC; Luo X; Ding H; Yang Y; Zhou B; Jiang H; Chen K; Luo C; Zheng M
    Org Biomol Chem; 2017 May; 15(17):3648-3661. PubMed ID: 28397890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
    Zhu K; Shao J; Tao H; Yan X; Luo C; Zhang H; Duan W
    J Comput Aided Mol Des; 2019 Aug; 33(8):775-785. PubMed ID: 31312965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Selective, Cell Active Inhibitors of Protein Arginine Methyltransferase 5 through Structure-Based Virtual Screening and Biological Assays.
    Ye F; Zhang W; Ye X; Jin J; Lv Z; Luo C
    J Chem Inf Model; 2018 May; 58(5):1066-1073. PubMed ID: 29672052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations.
    Ji S; Ma S; Wang WJ; Huang SZ; Wang TQ; Xiang R; Hu YG; Chen Q; Li LL; Yang SY
    Chem Biol Drug Des; 2017 Apr; 89(4):585-598. PubMed ID: 27714957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of PRMT5 inhibitors with novel scaffold structures through virtual screening and biological evaluations.
    Zhang Q; Zhang L; Jin J; Fan Y; Wang X; Hu H; Ye X; Wang L; Cao C; Ye F
    J Mol Model; 2022 Jun; 28(7):184. PubMed ID: 35680707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective small-chemical inhibitors of protein arginine methyltransferase 5 with anti-lung cancer activity.
    Kong GM; Yu M; Gu Z; Chen Z; Xu RM; O'Bryant D; Wang Z
    PLoS One; 2017; 12(8):e0181601. PubMed ID: 28806746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)--Hit to Lead studies.
    Wan H; Huynh T; Pang S; Geng J; Vaccaro W; Poss MA; Trainor GL; Lorenzi MV; Gottardis M; Jayaraman L; Purandare AV
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5063-6. PubMed ID: 19632837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation.
    Shao J; Zhu K; Du D; Zhang Y; Tao H; Chen Z; Jiang H; Chen K; Luo C; Duan W
    Eur J Med Chem; 2019 Feb; 164():317-333. PubMed ID: 30605830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arginine Methyltransferase 5 (PRMT5) Inhibitors with 3-(1H-benzo[d]imidazol- 2-yl)anilines Core Identified by Virtual Screening and Biological Evaluation.
    Zhang Y; Zhu K; Zhang J; Zhang JH; Song Z; Zhang X; Liu SK; Jiang CS
    Curr Pharm Des; 2023; 29(6):474-479. PubMed ID: 36790004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
    Wang Y; Hu W; Yuan Y
    J Med Chem; 2018 Nov; 61(21):9429-9441. PubMed ID: 29870258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction assessments of the first S-adenosylmethionine competitive inhibitor and the essential interacting partner methylosome protein 50 with protein arginine methyltransferase 5 by combined computational methods.
    Zhu K; Jiang CS; Hu J; Liu X; Yan X; Tao H; Luo C; Zhang H
    Biochem Biophys Res Commun; 2018 Jan; 495(1):721-727. PubMed ID: 29154828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of 1-phenyl-tetrahydro-β-carboline-based first dual PRMT5/EGFR inhibitors as potential anticancer agents.
    Zhang J; Liu X; Sa N; Zhang JH; Cai YS; Wang KM; Xu W; Jiang CS; Zhu KK
    Eur J Med Chem; 2024 Apr; 269():116341. PubMed ID: 38518523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
    Sloan SL; Renaldo KA; Long M; Chung JH; Courtney LE; Shilo K; Youssef Y; Schlotter S; Brown F; Klamer BG; Zhang X; Yilmaz AS; Ozer HG; Valli VE; Vaddi K; Scherle P; Alinari L; Kisseberth WC; Baiocchi RA
    PLoS One; 2021; 16(5):e0250839. PubMed ID: 33989303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
    J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.